SGMT - NASDAQ
Sagimet Biosciences Inc.
$6.86
+1.3%Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
At a Glance
Live Snapshotsgmt
Total Assets
Last Annual Value
116.48M
3-Year CAGR
52%
5-Year CAGR
11%
10-Year CAGR
26%
Sagimet Biosciences Inc. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 Sagimet Biosciences Inc. NASDAQ:SGMT | 116.48M | 6.4% | 14.6% | N/A | |
 Voyager Therapeutics, Inc. NASDAQ:VYGR | 252.28M | -10.4% | 5.4% | 2.9% | |
 Atea Pharmaceuticals, Inc. NASDAQ:AVIR | 315.22M | -19.1% | -16.4% | N/A | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 257.59M | 23.5% | 6.2% | 10.1% | |
 Humacyte, Inc. NASDAQ:HUMA | 116.37M | -3.2% | -16.5% | N/A | |
 Caribou Biosciences, Inc. NASDAQ:CRBU | 175.37M | -26.0% | -16.9% | N/A | |
 Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | 280.73M | -15.3% | -8.6% | -0.0% | |
 SELLAS Life Sciences Group, Inc. NASDAQ:SLS | 78.34M | 132.7% | 24.3% | 1.8% | |
 Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | 271.15M | -14.2% | -7.1% | 18.1% | |
 Foghorn Therapeutics Inc. NASDAQ:FHTX | 198.10M | -11.5% | -17.5% | N/A | |
 Zura Bio Limited NASDAQ:ZURA | 113.95M | 4.2% | -4.1% | N/A |
Sagimet Biosciences Inc. Fair Value Envelope
Related Guides
Continue your SGMT research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.